Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Roche Builds Hematology Pipeline Beyond B-Cell Disease

Executive Summary

Roche is not content with replacing its aging Rituxan franchise in blood cancers. At ASCO, the company described its long-term plans to solidify Gazyva as the new CD20 backbone for non-Hodgkin lymphomas while using Venclexta and even newer candidates like targeted therapy idasanutlin to extend into new blood cancer indications – including the high-need acute myeloid leukemia space.

Advertisement

Related Content

Celgene’s Otezla Shines, On Track To Be A Fourth Blockbuster Pillar
Roche’s Gazyva Clears FDA, But First Breakthrough Approval Breaks No Speed Barriers

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register